Therapeutic Efficacy of Cannabidiol (CBD): a Review of the Evidence From Clinical Trials and Human Laboratory Studies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Clinical Psychology
Link
https://link.springer.com/content/pdf/10.1007/s40429-020-00326-8.pdf
Reference56 articles.
1. • Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. Jama. 2017;318(17):1708–9. https://doi.org/10.1001/jama.2017.11909This study analyzed commercially-available CBD extracts. 69% were labeled inaccurately (43% underlabeled, 26% overlabeled for CBD concentrations) and 21% contained THC (up to 6.4 mg/mL).
2. Gurley BJ, Murphy TP, Gul W, Walker LA, ElSohly M. Content versus label claims in cannabidiol (CBD)-containing products obtained from commercial outlets in the state of Mississippi. J Diet Suppl. 2020:1–9. https://doi.org/10.1080/19390211.2020.1766634.
3. Poklis JL, Mulder HA, Peace MR. The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids. Forensic Sci Int. 2019;294:e25–e7. https://doi.org/10.1016/j.forsciint.2018.10.019.
4. Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741–53. https://doi.org/10.1136/jnnp-2017-317,168.
5. • Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–8. https://doi.org/10.1016/s1474-4422(15)00379-8In a 12-week open-label trial, oral CBD (2-5 mg/kg/day, increased to maximum dose of 25-50 mg/kg/day) reduced monthly motor seizures by 36.5% (median) among patients (ages 1-30 years) with severe, intractable, childhood-onset, treatment-resistant epilepsy. This study supported the FDA approval of CBD (i.e., Epidiolex®) to treat seizures associated with Lennox-Gastaut and Dravet syndromes.
Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cannabidiol and neurodegeneration: From molecular mechanisms to clinical benefits;Ageing Research Reviews;2024-09
2. TRPV1 channel in the pathophysiology of epilepsy and its potential as a molecular target for the development of new antiseizure drug candidates;Progress in Neurobiology;2024-09
3. Exploratory survey study on adjunctive use of medical cannabis for Gaucher disease;Rare Disease and Orphan Drugs Journal;2024-08-23
4. A comprehensive update on cannabidiol, its formulations and drug delivery systems;Phytochemistry Reviews;2024-08-09
5. Differential Contributions of CA3 and Entorhinal Cortex Inputs to Ripple Patterns in the Hippocampus Under Cannabidiol;2024-08-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3